BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Chautant F, Guillaume M, Robic MA, Cadranel JF, Peron JM, Lison H, Cool C, Bureau C, Duhalde V. Lessons from “real life experience” of rifaximin use in the management of recurrent hepatic encephalopathy. World J Hepatol 2020; 12(1): 10-20 [PMID: 31984117 DOI: 10.4254/wjh.v12.i1.10]
URL: https://www.wjgnet.com/1948-5182/full/v12/i1/10.htm
Number Citing Articles
1
Yasunari Hiramine, Hirofumi Uto, Seiichi Mawatari, Shuji Kanmura, Yasushi Imamura, Takuya Hiwaki, Akiko Saishoji, Atsuko Kakihara, Shigeho Maenohara, Koichi Tokushige, Akio Ido. Efficacy of rifaximin, a poorly absorbed rifamycin antimicrobial agent, for hepatic encephalopathy in Japanese patientsHepatology Research 2021; 51(4): 445 doi: 10.1111/hepr.13622
2
Robert S. Rahimi, Kimberly A. Brown, Steven L. Flamm, Robert S. Brown. Overt Hepatic Encephalopathy: Current Pharmacologic Treatments and Improving Clinical OutcomesThe American Journal of Medicine 2021;  doi: 10.1016/j.amjmed.2021.06.007